User menu

Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)

Bibliographic reference Harousseau, Jean-Luc ; Avet-Loiseau, Herve ; Facon, Thierry ; Attal, Michel ; Doyen, Chantal ; et. al. Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).51st Annual Meeting of the American-Society-of-Hematology (New Orleans(La), Dec 05-08, 2009). In: Blood, Vol. 114, no. 22, p. 150 (2009)
Permanent URL http://hdl.handle.net/2078.1/58700